[HTML] nature.com

[HTML][HTML] Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

TW Jenkins, SL Downey-Kopyscinski, JL Fields… - Scientific Reports, 2021 - nature.com
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …
被引用次数：27 相关文章

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.

TW Jenkins, SL Downey-Kopyscinski, JL Fields… - Scientific …, 2021 - europepmc.org
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein

TW Jenkins, SL Downey-Kopyscinski… - Scientific …, 2021 - ui.adsabs.harvard.edu
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

TW Jenkins, SL Downey-Kopyscinski… - Scientific …, 2021 - digitalcommons.dartmouth.edu
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …
[HTML] nih.gov

[HTML][HTML] Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

TW Jenkins, SL Downey-Kopyscinski, JL Fields… - Scientific …, 2021 - ncbi.nlm.nih.gov
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein

TW Jenkins, SL Downey-Kopyscinski… - Scientific …, 2021 - pubmed.ncbi.nlm.nih.gov
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein.

TW Jenkins, SL Downey-Kopyscinski… - Scientific …, 2021 - search.ebscohost.com
Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …